IGF1 and pancreatic neoplasm: Ireland et al. demonstrated that TAMs and CAFs are major sources of IGF-1 and IGF-2 in breast and pancreatic tumors; and IGF signaling is implicated in the breast and pancreatic tumor resistance to paclitaxel and gemcitabine, respectively (337, 338).